Future Science Group (FSG) is pleased to announce it has expanded its partnership with ScienceOpen, with two new collections featuring the journals BioTechniques and Future Drug Discovery.
ScienceOpen is an interactive discovery platform that provides advanced search functions along with options such as post-publication review and recommendations.
"Discovery of scientific research, and being able to see that research in context, is hugely important to enable further, successful scientific research," explained Francesca Lake, Head of Open Access Publishing at Future Science Group. "At Future Science Group we support ScienceOpen's mission to facilitate open and public communication between academics, and are delighted to be partnering with them on these two exciting journals."
BioTechniques launched in 1983 and is a leading peer-reviewed journal for methods-related research in the life sciences.
Future Drug Discovery launched in 2019, and provides readers with an open access and high quality source of methods, research and review articles covering the entire drug discovery, R&D pipeline, alongside opinion articles discussing the field at large.
Stephanie Dawson, CEO of ScienceOpen, commented "In fast moving fields like drug discovery and biotech it is essential to get research published as quickly and distributed as widely as possible. We are thrilled to support the Future Science Group with two new open access journals that are pushing their fields forward and exploring open communication around their content."
About Future Science Group
Founded in 2001, FSG is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio consists of three imprints, Future Medicine, Future Science and Newlands Press, publishing both eBooks and journals. In addition to this core publishing business, FSG develops specialist knowledge networks and content hubs, enabling professionals to easily connect and collaborate with their peers in niche scientific fields.
FSG currently publishes 34 peer-reviewed journals as well as 8 knowledge networks and content hubs across a wide range of therapy area and scientific fields. Key journals include Future Microbiology, Future Oncology and the Journal of Comparative Effectiveness Research, alongside sites such as Infectious Diseases Hub, Oncology Central and The Evidence Base.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.
From promotional collections to Open Access hosting and full publishing packages, ScienceOpen provides next-generation services to academic publishers embedded in an interactive discovery platform. ScienceOpen was founded in 2013 in Berlin and Boston by Alexander Grossmann and Tibor Tscheke to accelerate research communication.